Premium
Clinical Efficacy and Toxicity Profile of Tacrolimus and Mycophenolic Acid in Relation to Combined Long‐term Pharmacokinetics in de Novo Renal Allograft Recipients
Author(s) -
Kuypers Dirk R. J.,
Claes Kathleen,
Evenepoel Pieter,
Maes Bart,
Vanrenterghem Yves
Publication year - 2004
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2003.12.009
Subject(s) - mycophenolic acid , tacrolimus , medicine , leukopenia , pharmacokinetics , therapeutic drug monitoring , toxicity , pharmacology , gastroenterology , transplantation , urology
Tacrolimus and mycophenolate mofetil are effective drugs characterized by specific toxicity profiles that may compromise their long‐term use in renal transplant recipients. Clinicians, therefore, need reliable drug monitoring tools for relating efficacy and toxicity to drug exposure. Study design We conducted a prospective 12‐month pharmacokinetic study of tacrolimus and mycophenolic acid in 100 de novo recipients. The aim was to examine whether tacrolimus and mycophenolic acid exposure parameters (predose trough blood concentration [C 0 ], area under the concentration curve from 0 to 12 hours [AUC 0–12 ], maximum blood or plasma concentration [C max ], and dose) would reflect clinical efficacy and toxicity at different time points after transplantation (7 days, 6 weeks, and 3, 6, and 12 months). Results Initially, after grafting, the tacrolimus AUC 0–12 was higher in recipients with infection ( P = .01 on day 7, P = .02 at week 6), whereas the mycophenolic acid AUC 0–12 was not different. There was no difference in tacrolimus exposure between patients who had arterial hypertension or hyperlipidemia and those who did not. Patients with tacrolimus nephrotoxicity received a higher drug dose ( P = .03) and had higher drug clearance ( P = .02). From 3 months, recipients with anemia or leukopenia had higher mycophenolic acid AUC 0–12 (anemia, P = .03 at month 3 and P = .01 at month 12; leukopenia, P = .01 at month 3 and P = .04 at 1 year) and C 0 (anemia, P = .001 at month 3 and P = .001 at month 12; leukopenia, P = .01 at month 3 and P = .04 at 1 year). Finally, for recipients who did not simultaneously have a target tacrolimus AUC 0–12 of 150 ng · h/mL and a mycophenolic acid AUC 0–12 of 45 mg · h/L by day 7, the incidence of acute rejection tended to be higher (26.3%) compared with patients who reached both target values (7.7%) ( P = .07). Conclusions Pharmacokinetic exposure parameters of tacrolimus and mycophenolic acid are related to specific drug‐induced side effects in a time‐dependent fashion. In addition, this study has provided a conceptual basis for defining a combined target therapeutic window for tacrolimus and mycophenolic acid based on sparse AUC 0–12 measurements. Clinical Pharmacology & Therapeutics (2004) 75 , 434–447; doi: 10.1016/j.clpt.2003.12.009